References

rpcardio

Rational Pharmacotherapy in Cardiology

Рациональная Фармакотерапия в Кардиологии

1819-64462225-3653

«SILICEA-POLIGRAF» LLC

10.20996/1819-6446-2008-4-2-58-65

rpcardio-1094

Research Article

POINT OF VIEW

ТОЧКА ЗРЕНИЯ

ACUTE CORONARY SYNDROME IN PATIENTS WITH DIABETES MELLITUS: ON THE WAY TO MUNICH-2008

ОСТРЫЙ КОРОНАРНЫЙ СИНДРОМ У БОЛЬНЫХ САХАРНЫМ ДИАБЕТОМ: НА ПУТИ К МЮНХЕНУ-2008

Дедов

И. И.

Dedov

I. I.

Александров

Ан. А.

Alexanrov

A. A.

Эндокринологический научный центр Росмедтехнологий, МоскваРоссияEndocrinology scientific center of Rosmedtechnology, MoscowRussian Federation

2008

29012016

425865

2016

Дедов И.И., Александров А.А.

Dedov I.I., Alexanrov A.A.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.rpcardio.online/jour/article/view/1094

Results of trials on the therapy of patients with acute myocardial infarction (MI) and glucose metabolism disturbances are discussed. According to author’s data, 67% of patients with MI have glucose tolerance disturbances including 44% of patient with these reaching the level of diabetes mellitus (DM). Mortality risk in patients with MI and DM is some times higher than this in patients with MI without glucose metabolism disturbances. Active glucose correction results in significant mortality risk reduction. It is necessary to reduce glucose blood level to normal one as soon as possible in patients with MI and DM. It can be managed with insulin, if the glucose blood level is intensively increased or with per oral glucose lowering medicines, if there is moderate hyperglycemia. In spite of wide usage of these class drugs, it is not still clear which medicine is mostly effective in patients with MI and glucose metabolism disturbances.

Обсуждаются результаты исследований по лечению больных острым инфарктом миокарда (ОИМ) с нарушениями углеводного обмена. По данным авторов, у 67% больных ОИМ имеются нарушения толерантности к глюкозе, а у 44% больных они достигают уровня сахарного диабета (СД). Риск смерти в результате ОИМ у больных СД в несколько раз выше, чем у лиц без нарушения углеводного обмена. Интенсивная коррекция глюкозы крови приводит к выраженному снижению смертности. У больных СД с ОИМ необходимо как можно быстрее снизить концентрацию глюкозы в крови до нормы. При резко повышенном уровне глюкозы это может быть сделано с помощью инсулина, а при умеренном повышении – с помощью пероральных сахароснижающих препаратов. Несмотря на широкое применение препаратов этой группы, остается неясным, какой препарат является наиболее эффективным у больных ОИМ с нарушением углеводного обмена.

острый инфаркт миокардасахарный диабетнарушение углеводного обмена

acute myocardial infarctiondiabetes mellitusglucose metabolism disturbances

References1

Ryden L., Standl E., Bartnik M. et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. Eur Heart J 2007; 28: 88–136.

Александров А.А., Оганов Р.Г., Бунаева В.Е., Виноградова И.В. Воздействие на метаболизм сердца у больных острым инфарктом миокарда. Кардиология. 1977;(4): 22–9.

Bartnik M, Ryden L, Ferrari R et al. Euro Heart Surveiу Investigаstors. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J 2004; 25: 1880–90.

Bartnik M. Glucose regulation and coronary artery disease. Studies on prevalence, recognition and prognostic implication. Karolinska Institutet, Stockholm, 2005.

Malmberg K, Ryden L. Myocardial infarction in patients with diabetes mellitus. Eur Heart J 1988;9:259–64.

Karlson BW, Herlitz J, Hjalmarson A. Prognosis of acute myocardial infarction in diabetic and non-diabetic patients. Diabet Med 1993; 10 (5): 449–54.

Rytter L, Beck-Nielsen H, Troelsen S. Diabetic patients and myocardial infarction. Acta Endocrinologica 1984; suppl. 262: 83–7.

Herlitz J, Malmberg K, Karlson B et al. Mortality and morbidity during a five year follow-up of diabetics with myocardial infarction. Acta Med Scand 1988;224:31–8.

Ulvenstam G, Aberg A, Bergstrand R et al. Long-term prognosis after myocardial infarction in men with diabetes. Diabetes 1985; 34: 787–92.

Orlander PR, Goff DC, Morrissey M et al. The relation of diabetes to the severity of acute myocardial infarction and post-myocardial infarction survival in Mexican-Americans and non-Hispanic whites. The Corpus Christi heart project. Diabetes 1994; 43 (7): 897–902.

Jaffe AS, Spadaro JJ, Schechtman K et al. Increased congestive heart failure after myocardial infarction of modest extent in patients with diabetes mellitus. Am Heart J 1984; 108: 31–7.

Abbud ZA, Shindler DM, Wilson AC, Kostis JB. Effect of diabetes mellitus on short and long-term mortality rates of patients with acute myocardial infarction: a statewide study. Myocardial infarction Data Acquisition System Study Group. Am Heart J 1995; 130: 51–8.

Smith JW, Marcus FI, Serokman R. Prognosis of patients with diabetes mellitus after acute myocardial infarction. Am J Cardiol 1984; 54: 718–21.

Granger CB, Califf RM, Young S et al. Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. The thrombolysis and angioplasty in myocardial infarction (TAMI) study group. J Am Coll Cardiol 1993; 21 (4): 920–5.

Singer DE, Moulton AW, Nathan DM. Diabetic myocardial infarction. Interaction of diabetes with other preinfarction risk factors. Diabetes 1989; 38: 350–7.

Stone PH, Muller JE, Hartwell T et al. The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. The MILIS study group. J Am Coll Cardiol 1989; 14; 49–57.

Savage MP, Krolewski AS, Kenien GG et al. Acute myocardial infarction in diabetes mellitus and significance of congestive heart failure as a prognostic factor. Am J Cardiol 1988; 62: 665-9.

Jacoby RM, Nesto RW. Acute myocardial infarction in the diabetic patients: pathophysiology, clinical course and prognosis. J Am Coll Cardiol 1992; 20: 736–44.

Bartnik M, Rydén L, Ferrari R, et al on behalf of the Euro Heart Survey Investigators. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe: The Euro Heart Survey on diabetes and the heart. Eur Heart J 2004; 25: 1880-90.

Malmberg K, Norhammar A, Wedel H, Rydén L. Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction : Long-Term Results From the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) Study. Circulation 1999; 99: 2626 – 32

Rogers WJ, Segall PH, McDaniel HG, et al. Prospective randomized trial of glucose-insulin-potassium in acute myocardial infarction: effects on myocardial hemodynamics, substrates and rhythm. Am J Cardiol 1979;43:801-9.

Malmberg K., Rydén L, Wedel H. et al, for the DIGAMI 2 Investigator. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 2005; 26: 650-61.

Brady PA, Al-Suwaidi J, Kopecky SL, Terzic A. Sulfonylureas and mortality in diabetic patients after myocardial infarction. Circulation 1998; 97: 709–10.

Halkin A, Roth A, Jonas M, Behar S. Sulfonylureas are not associated with increased mortality in diabetics treated with thrombolysis for acute myocardial infarction. J Thromb Thrombolysis 2001; 12: 177–84.

Klamann A, Sarfert P, Launhardt V. et al. Myocardial infarction in diabetic vs nondiabetic subjects. Survival and infarct size following therapy with sulfonylureas (glibencklamide). Eur Heart J 2000; 21: 220–9.

Aronow WS, Ahn C. Incidence of new coronary events in older persons with diabetes mellitus and prior myocardial infarction treated with sulfonylureas, insulin, metformin, and diet alone. Am J Cardiol 2001; 88: 556–7.

Jollis JG, Simpson RJ Jr, Cascio WE et al. Relation between sulfonylurea therapy, complications, and outcome for elderly patients with acute myocardial infarction. Am Heart J 1999; 138 (5 Pt 1): S376–80.

Thisted H, Johnsen SP, Rungby J. Sulfonylureas and the risk of myocardial infarction. Metabolism. 2006; 55 (5 Suppl. 1): S16–S19.

Danchin N., Charpentier G., Ledru F. et al. Role of previous treatment with sulfonylureas in diabetic patients with acute myocardial infarction: results from a nationwide French registry. Diabetes Metab Res Rev 2005; 21: 143–9.

Gustafsson I., Hildebrandt P., Seibaek M. et al. Long-term prognosis of diabetic patients with myocardial infarction: relation to antidiabetic treatment regimen. The TRACE Study Group. Eur Heart J 2000; 21: 1937–43.

The authors declare that there are no conflicts of interest present.